Abstract
BIO89-100, a GlycoPEGylated FGF21 Analog, Improved Serum Lipids and Extended Half-Life in a Controlled Single Ascending Dose Trial in Healthy Subjects†
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have